science wire
« BACK
Pharmacology - Health - 22.05.2019
Health - Pharmacology - 21.05.2019
Pharmacology - Health - 21.05.2019 
Treating muscular disease - Santhera and Biozentrum join forces
Santhera Pharmaceuticals and the University of Basel's Biozentrum announce their collaboration to advance gene therapy research for the treatment of congenital muscular dystrophy.
Pharmacology - 21.05.2019
Pharmacology - Health - 16.05.2019
Health - Pharmacology - 16.05.2019
Pharmacology - Health - 16.05.2019
Pharmacology - Chemistry - 15.05.2019
Health - Pharmacology - 14.05.2019
Health - Pharmacology - 14.05.2019
Pharmacology - Health - 10.05.2019
Health - Pharmacology - 10.05.2019
Pharmacology - Health - 09.05.2019
Pharmacology - Health - 09.05.2019
Pharmacology - 08.05.2019
Pharmacology - Health - 08.05.2019
Health - Pharmacology - 07.05.2019
Innovation / Technology - Pharmacology - 07.05.2019
Health - Pharmacology - 07.05.2019
Pharmacology - Health - 06.05.2019
Pharmacology - Health - 02.05.2019
Health - Pharmacology - 02.05.2019
Pharmacology - 01.05.2019
Pharmacology - Health - 30.04.2019
Health - Pharmacology - 30.04.2019
Pharmacology - Life Sciences - 30.04.2019
Pharmacology - Health - 29.04.2019
Health - Pharmacology - 25.04.2019
Pharmacology - Health - 24.04.2019
Health - Pharmacology - 24.04.2019 
Two Decades of Swiss Leadership for New Malaria Medicines
On World Malaria Day 2019, Swiss organizations look back on a long history of successful public-private collaboration for new malaria medicines.
Pharmacology - Business / Economics - 24.04.2019
Pharmacology - Health - 23.04.2019
Health - Pharmacology - 23.04.2019
Health - Pharmacology - 17.04.2019
Pharmacology - Health - 15.04.2019
Pharmacology - Health - 15.04.2019
Pharmacology - Health - 12.04.2019
Pharmacology - Health - 12.04.2019 
Queensland researchers join international search for new antibiotics
In an Australian-first, The University of Queensland will join forces with the Global Antibiotic Research and Development Partnership (GARDP) to tackle the growing problem of drug-resistant infections. GARDP, a not-for-profit research and development group initiated by the World Health Organization, develops new or improved antibiotic treatments.
Pharmacology - 12.04.2019
Pharmacology - Health - 11.04.2019
Pharmacology - Business / Economics - 09.04.2019
Pharmacology - Health - 09.04.2019 
Open source drug research could open up medicine
Universal access to medicine could come via open source drug discovery, argues lecturer Dr Alice Motion.
Health - Pharmacology - 05.04.2019
Pharmacology - 04.04.2019
Health - Pharmacology - 04.04.2019 
New Project on Child Health in Tanzania
Fondation Botnar has awarded CHF 7 million to researchers from Lausanne for further deployment of electronic diagnostic and treatment tools based on algorithms, which will help clinicians to manage febrile children.
Health - Pharmacology - 03.04.2019
Pharmacology - Health - 03.04.2019
Pharmacology - Health - 02.04.2019
Pharmacology - Health - 01.04.2019
Health - Pharmacology - 01.04.2019
Pharmacology
Results 51 - 100 of 1314.
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
New inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate - IND/GLY/MF) was superior to the standard of care (long-acting beta-agonist/inhaled c
New inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate - IND/GLY/MF) was superior to the standard of care (long-acting beta-agonist/inhaled c
Bern Center for Precision Medicine inaugurated
The Bern Center for Precision Medicine (BCPM) of the University of Bern and Inselspital, University hospital of Bern, were officially opened today in the presence of Director of Education Christine Häsler.
The Bern Center for Precision Medicine (BCPM) of the University of Bern and Inselspital, University hospital of Bern, were officially opened today in the presence of Director of Education Christine Häsler.
Santhera Pharmaceuticals and the University of Basel's Biozentrum announce their collaboration to advance gene therapy research for the treatment of congenital muscular dystrophy.
Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders
Overall survival results from MONALEESA-7 with Kisqali (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO Primary results of
Overall survival results from MONALEESA-7 with Kisqali (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO Primary results of
Roche’s personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents
Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour types harbouring neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kina
Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour types harbouring neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kina
Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia
Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta off
Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta off
New Roche test aids clinicians in accelerating tuberculosis diagnosis and treatment by detecting antimicrobial resistance within the world’s leading cause of infectious disease deaths
New tests on cobas 6800/8800 systems provide clinicians information to help speed treatment and reduce the spread of infection Rising challenge of drug resistance compounds the tuberculosis global health crisis Mycobacteria test menu allows detection of tuberculosis, drug resistant tuberculosis and nontuberculous mycobacteria infections from single patient sample Roche today announced the CE-IVD launch of the cobas MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA.
New tests on cobas 6800/8800 systems provide clinicians information to help speed treatment and reduce the spread of infection Rising challenge of drug resistance compounds the tuberculosis global health crisis Mycobacteria test menu allows detection of tuberculosis, drug resistant tuberculosis and nontuberculous mycobacteria infections from single patient sample Roche today announced the CE-IVD launch of the cobas MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA.
Major UK clinical trial for Group B Strep screening in pregnant women announced
A landmark clinical trial is aiming to improve the prevention of potentially life-threatening infection caused by group B Streptococcus in newborn babies in the UK.
A landmark clinical trial is aiming to improve the prevention of potentially life-threatening infection caused by group B Streptococcus in newborn babies in the UK.
Novartis data at AAN show Gilenya is the first and only disease-modifying therapy with proven superiority versus glatiramer acetate in relapsing remitting MS
Full results from the ASSESS study demonstrate patients with relapsing remitting multiple sclerosis (RRMS) taking Gilenya (fingolimod) 0.5mg had significantly fewer relapses than patients taking glatiramer acetate 20mg Gilenya showed significant superiority versus glatiramer acetate in other key measures of disease activity, such as brain lesions There were more discontinuations on glatiramer acetate compared to Gilenya reinforcing Gil
Full results from the ASSESS study demonstrate patients with relapsing remitting multiple sclerosis (RRMS) taking Gilenya (fingolimod) 0.5mg had significantly fewer relapses than patients taking glatiramer acetate 20mg Gilenya showed significant superiority versus glatiramer acetate in other key measures of disease activity, such as brain lesions There were more discontinuations on glatiramer acetate compared to Gilenya reinforcing Gil
Roche to present new data highlighting comprehensive approach to cancer care at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Study results across 17 medicines reflect our commitment to personalised care with advances in targeted therapies, immunotherapy, and diagnostics, data and analytics New pivotal data on fixed-duratio
Study results across 17 medicines reflect our commitment to personalised care with advances in targeted therapies, immunotherapy, and diagnostics, data and analytics New pivotal data on fixed-duratio
Novartis data at AAN show Mayzent’s positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS
Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent (siponimod) had a meaningful benefit on cognitive processing speed (CPS) for these patients Impairment in cognitive function, one of the most disabling aspects of MS, affects 50-70% of patients and is more severe in patients with SPMS EXPAND findings demonstrate that SPMS patients treated earlier in the cou
Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent (siponimod) had a meaningful benefit on cognitive processing speed (CPS) for these patients Impairment in cognitive function, one of the most disabling aspects of MS, affects 50-70% of patients and is more severe in patients with SPMS EXPAND findings demonstrate that SPMS patients treated earlier in the cou
New AveXis data at AAN showed long-term durability of Zolgensma in patients with spinal muscular atrophy (SMA) Type 1
Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial Mean age of follow-up since dosing with Zolge
Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial Mean age of follow-up since dosing with Zolge
’Adopt-a-hive’ scheme for schools
A leading Wales learning technology company, Aspire 2Be, is teaming up with Cardiff University to encourage school pupils to learn about the importance of bees and beekeeping.
A leading Wales learning technology company, Aspire 2Be, is teaming up with Cardiff University to encourage school pupils to learn about the importance of bees and beekeeping.
Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians evaluate and discuss early signs of progression to secondary progressive MS
Up to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS) , a stage of the disease leading to continuous functional decline, which is often undiagnosed or diagnosed only retrospectively Data presented at AAN show that MSProDiscuss TM , a scientifically-validated digital tool, was able to provide information to support differentiation between RRMS and SPMS with high sensitivity and specificity These fin
Up to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS) , a stage of the disease leading to continuous functional decline, which is often undiagnosed or diagnosed only retrospectively Data presented at AAN show that MSProDiscuss TM , a scientifically-validated digital tool, was able to provide information to support differentiation between RRMS and SPMS with high sensitivity and specificity These fin
FDA approves Roche’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The
The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The
Novartis to highlight extensive long-term safety and efficacy data of Aimovig across the spectrum of migraine at AAN
After long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average Separate study showed
After long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average Separate study showed
Yale joins NIH research network aimed at improving maternal-fetal health
High-impact research that makes its way into clinical practice is made possible thanks to large-scale multicenter clinical trials.
High-impact research that makes its way into clinical practice is made possible thanks to large-scale multicenter clinical trials.
New data at AAN reinforce Novartis commitment to transforming the lives of people of all ages who live with neurological conditions
Novartis leads the way at AAN with 53 abstracts, showcasing its broad portfolio of transformative medicines and innovative solutions for people living with spinal muscular atrophy (SMA), multiple scl
Novartis leads the way at AAN with 53 abstracts, showcasing its broad portfolio of transformative medicines and innovative solutions for people living with spinal muscular atrophy (SMA), multiple scl
Researchers create the first maps of two melatonin receptors essential for sleep
Share This Article The behavior of humans and all animals is governed by a variety of natural cycles.
Share This Article The behavior of humans and all animals is governed by a variety of natural cycles.
New Roche data at the 2019 AAN Annual Meeting showcase breadth and promise of neuroscience portfolio
Risdiplam data from Part 1 of pivotal FIREFISH study show infants with Type 1 spinal muscular atrophy achieve key motor milestones and improved survival after one year of treatment New analyses in re
Risdiplam data from Part 1 of pivotal FIREFISH study show infants with Type 1 spinal muscular atrophy achieve key motor milestones and improved survival after one year of treatment New analyses in re
On World Malaria Day 2019, Swiss organizations look back on a long history of successful public-private collaboration for new malaria medicines.
Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy
Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year, and more than 620,000 people will die from the disease.
Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year, and more than 620,000 people will die from the disease.
Sniffles and sneezes: A Q&A about allergies with Dr. Ryan Steele
With allergy season upon us, YaleNews spoke to Dr. Ryan Steele , instructor of clinical medicine at Yale School of Medicine, about the current season, prevention, treatments, and other facts allergy sufferers need to know.
With allergy season upon us, YaleNews spoke to Dr. Ryan Steele , instructor of clinical medicine at Yale School of Medicine, about the current season, prevention, treatments, and other facts allergy sufferers need to know.
Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
By 2020, over 1.5 million people in the US are likely to have wet AMD, the leading cause of blindness in industrialized countries Filing is based on Phase III data from the HAWK and HARRIER
By 2020, over 1.5 million people in the US are likely to have wet AMD, the leading cause of blindness in industrialized countries Filing is based on Phase III data from the HAWK and HARRIER
Innovative Medicines Initiative Launches Translational Safety Biomarker Pipeline Project
The University of Zurich coordinates a worldwide research project that focuses on the development of new biomarkers.
The University of Zurich coordinates a worldwide research project that focuses on the development of new biomarkers.
’Pharmabees’ to make honey cosmetics
Cardiff University is joining forces with a North Wales company to produce a new brand of natural cosmetics, Celtic Wellbeing.
Cardiff University is joining forces with a North Wales company to produce a new brand of natural cosmetics, Celtic Wellbeing.
In an Australian-first, The University of Queensland will join forces with the Global Antibiotic Research and Development Partnership (GARDP) to tackle the growing problem of drug-resistant infections. GARDP, a not-for-profit research and development group initiated by the World Health Organization, develops new or improved antibiotic treatments.
Computational power in the fight against cancer
Vittorio Limongelli, Associate professor at the USI Faculty of Biomedical Sciences and at the USI Institute of Computational Science (ICS), has recently received a competitive research funding consis
Vittorio Limongelli, Associate professor at the USI Faculty of Biomedical Sciences and at the USI Institute of Computational Science (ICS), has recently received a competitive research funding consis
Universal access to medicine could come via open source drug discovery, argues lecturer Dr Alice Motion.
Brexit threat to Sam's legacy in EU children's brain tumour research
A leading expert in childhood cancer is warning that life-saving changes to European clinical trials regulations that were inspired by the story of a young brain tumour patient of his, won't benefit children in the UK after Brexit.
A leading expert in childhood cancer is warning that life-saving changes to European clinical trials regulations that were inspired by the story of a young brain tumour patient of his, won't benefit children in the UK after Brexit.
Fondation Botnar has awarded CHF 7 million to researchers from Lausanne for further deployment of electronic diagnostic and treatment tools based on algorithms, which will help clinicians to manage febrile children.
Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc
Roche and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Act (the “HSR Act”) in connection with Roche's pending acquisition of Spark.
Roche and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Act (the “HSR Act”) in connection with Roche's pending acquisition of Spark.
Novartis first-in-class Cosentyx approved in China for psoriasis patients
China Health Authority NMPA approved Cosentyx (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Cosentyx is the first b
China Health Authority NMPA approved Cosentyx (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Cosentyx is the first b
AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
Facility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy AveXis plans
Facility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy AveXis plans